Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit
Belite Bio, a clinical-stage biopharmaceutical company (NASDAQ: BLTE) focusing on novel therapeutics for degenerative retinal diseases, has announced its participation in the Maxim Group 2024 Healthcare Virtual Summit. Dr. Hendrik P.N. Scholl, the company's Chief Medical Officer, will be part of the 'Ocular Drug Development' panel discussion.
The event is scheduled for Tuesday, October 15, 2024, at 11:00 am ET. Interested parties can access the live panel discussion through Maxim's M-Vest website. For registration and additional information, visitors are directed to https://m-vest.com/events/healthcare-10152024.
This participation underscores Belite Bio's commitment to advancing treatments for unmet medical needs in the field of degenerative retinal diseases.
Belite Bio, un'azienda biofarmaceutica in fase clinica (NASDAQ: BLTE) focalizzata su nuovi terapeutici per le malattie retiniche degenerative, ha annunciato la sua partecipazione al Maxim Group 2024 Healthcare Virtual Summit. Il Dott. Hendrik P.N. Scholl, Chief Medical Officer dell'azienda, sarà parte del panel di discussione 'Sviluppo di Farmaci Oculari'.
L'evento è programmato per martedì 15 ottobre 2024, alle 11:00 ora ET. Le parti interessate possono accedere alla discussione panel live attraverso il sito M-Vest di Maxim. Per la registrazione e ulteriori informazioni, i visitatori sono indirizzati a https://m-vest.com/events/healthcare-10152024.
Questa partecipazione sottolinea l'impegno di Belite Bio nell'avanzare i trattamenti per le necessità mediche insoddisfatte nel campo delle malattie retiniche degenerative.
Belite Bio, una empresa biofarmacéutica en etapa clínica (NASDAQ: BLTE) enfocada en nuevos tratamientos para enfermedades retinianas degenerativas, ha anunciado su participación en la Cumbre Virtual de Salud 2024 del Maxim Group. El Dr. Hendrik P.N. Scholl, Director Médico de la empresa, formará parte del panel de discusión 'Desarrollo de Fármacos Oculares'.
El evento está programado para el martes 15 de octubre de 2024, a las 11:00 am ET. Las partes interesadas pueden acceder a la discusión del panel en vivo a través del sitio web M-Vest de Maxim. Para registrarse y obtener información adicional, los visitantes deben dirigirse a https://m-vest.com/events/healthcare-10152024.
Esta participación resalta el compromiso de Belite Bio con el avance de tratamientos para necesidades médicas no satisfechas en el campo de las enfermedades retinianas degenerativas.
Belite Bio, 임상 단계의 생물제약 회사(NASDAQ: BLTE)로, 퇴행성 망막 질환을 위한 새로운 치료제를 중점적으로 다루고 있는 이 회사는 Maxim Group의 2024 헬스케어 가상 정상 회담에 참가할 것이라고 발표했습니다. Hendrik P.N. Scholl 박사, 회사의 최고 의학 책임자가 '안과 약물 개발' 패널 토론에 참여할 것입니다.
이 행사는 2024년 10월 15일 화요일, 오전 11:00 ET에 예정되어 있습니다. 관심 있는 parties는 Maxim의 M-Vest 웹사이트를 통해 라이브 패널 토론에 액세스할 수 있습니다. 등록 및 추가 정보는 방문객이 https://m-vest.com/events/healthcare-10152024로 안내됩니다.
이번 참여는 퇴행성 망막 질환 분야에서 충족되지 않은 의료 요구를 위해 치료법을 발전시키려는 Belite Bio의 의지를 강조합니다.
Belite Bio, une entreprise bio-pharmaceutique en phase clinique (NASDAQ: BLTE) axée sur des thérapeutiques novateurs pour les maladies rétiniennes dégénératives, a annoncé sa participation au Sommet Virtuel de la Santé 2024 de Maxim Group. Dr. Hendrik P.N. Scholl, le directeur médical de l'entreprise, participera à la discussion du panel 'Développement de Médicaments Oculaires'.
L'événement est prévu pour le mardi 15 octobre 2024, à 11h00 ET. Les parties intéressées peuvent accéder à la discussion de panel en direct via le site M-Vest de Maxim. Pour l'inscription et des informations supplémentaires, les visiteurs sont dirigés vers https://m-vest.com/events/healthcare-10152024.
Cette participation souligne l'engagement de Belite Bio à faire avancer les traitements pour les besoins médicaux non satisfaits dans le domaine des maladies rétiniennes dégénératives.
Belite Bio, ein biopharmazeutisches Unternehmen in der klinischen Phase (NASDAQ: BLTE), das sich auf neuartige Therapien für degenerative Netzhauterkrankungen konzentriert, hat seine Teilnahme am Maxim Group 2024 Healthcare Virtual Summit angekündigt. Dr. Hendrik P.N. Scholl, der Chief Medical Officer des Unternehmens, wird Teil der Podiumsdiskussion 'Entwicklung von Augenmedikamenten' sein.
Die Veranstaltung ist für Dienstag, 15. Oktober 2024, um 11:00 Uhr ET angesetzt. Interessierte Parteien können über die M-Vest-Website von Maxim auf die Live-Podiumsdiskussion zugreifen. Weitere Informationen und die Registrierung finden die Besucher unter https://m-vest.com/events/healthcare-10152024.
Diese Teilnahme unterstreicht das Engagement von Belite Bio, Behandlungen für nicht erfüllte medizinische Bedürfnisse im Bereich der degenerativen Netzhauterkrankungen voranzutreiben.
- None.
- None.
SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Hendrik P.N. Scholl, MD, MA, Chief Medical Officer of Belite Bio, will participate in the “Ocular Drug Development” panel discussion at the Maxim Group 2024 Healthcare Virtual Summit on Tuesday, October 15, 2024 at 11:00 am ET.
The live panel discussion can be accessed on Maxim’s M-Vest website. For more information and to sign up, please visit: https://m-vest.com/events/healthcare-10152024.
About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt Disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook or visit us at www.belitebio.com.
Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com
Julie Fallon
belite@argotpartners.com
FAQ
When is Belite Bio (BLTE) participating in the Maxim Group 2024 Healthcare Virtual Summit?
Who will represent Belite Bio (BLTE) at the Maxim Group 2024 Healthcare Virtual Summit?
What is the focus of Belite Bio's (BLTE) drug development efforts?
How can interested parties access the Belite Bio (BLTE) panel discussion at the Maxim Group summit?
